Aelis Farma: Availability of the 2023 Half-Year Financial Report
2023年9月27日 - 1:00AM
ビジネスワイヤ(英語)
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS), a
clinical-stage biopharmaceutical company focused on developing
treatments for brain diseases, today announces that its half-year
financial report has been made available to the public and filled
with the French Financial Markets Authority (Autorité des marchés
financiers).
It can be consulted on the Company's website,
www.aelisfarma.com, in the section
Investors/Documentation/Reports.
***
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical
company that is developing a new class of drugs, the
Signaling-Specific inhibitors of the CB1 receptor of the
endocannabinoid system (CB1-SSi). CB1-SSi have been developed by
Aelis Farma based on the discovery of a natural brain defense
mechanism made by the team led by Dr. Pier Vincenzo Piazza, the
Company’s CEO, when he was director of Neurocentre Magendie of the
INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi
appear to selectively inhibit the disease-related activity of the
CB1 receptor without disrupting its normal physiological activity.
CB1-SSi have consequently the potential to provide new treatments
for several brain diseases.
Aelis Farma is currently developing two first-in-class
clinical-stage drug candidates: AEF0117 for the treatment of CUD,
currently being tested in a phase 2b study in the United States;
and AEF0217 for cognitive disorders, including those of Down
Syndrome (Trisomy 21), currently in a phase 1/2 study in Spain in
people with Down syndrome. The Company also has a portfolio of new
innovative CB1-SSi for the treatment of other disorders associated
with a dysregulation of the activity of the CB1 receptor.
Aelis Farma draws on the talents of more than 20 highly
qualified employees.
For more information, visit www.aelisfarma.com and follow
us on LinkedIn and Twitter.
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
Disclaimer
Forward-looking statements Some information contained in
this press release are forward-looking statements, not historical
data. These forward-looking statements are based on current
beliefs, expectations, and assumptions, including, but not limited
to, assumptions about Aelis Farma's current and future strategy and
the environment in which Aelis Farma operates. They involve known
and unknown risks, uncertainties, and other factors, which may
cause actual results, performance, or achievements, or industry
results or other events, to differ materially from those described
or implied by such forward-looking statements. These risks and
uncertainties include those set out and described in detail in
Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration
Document approved by the Autorité des Marchés Financiers on April
26, 2023, under number R.23-018.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions, or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926051198/en/
AELIS FARMA Pier Vincenzo Piazza CEO
contact@aelisfarma.com
NewCap Dusan Oresansky/Aurélie Manavarere Investor
Relations aelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur Rouillé Media Relations aelis@newcap.fr +33
1 44 71 00 15
Aelis Farma (EU:AELIS)
過去 株価チャート
から 4 2024 まで 5 2024
Aelis Farma (EU:AELIS)
過去 株価チャート
から 5 2023 まで 5 2024